CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.
about
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisAntibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell linesPhylogenetic analysis of the MS4A and TMEM176 gene familiesProteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain.Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphomaCD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest.Meta-analysis of association between the genetic polymorphisms on chromosome 11q and Alzheimer's disease susceptibility.Expression of MS4A and TMEM176 Genes in Human B LymphocytesA Family of non-GPCR Chemosensors Defines an Alternative Logic for Mammalian Olfaction.Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.MS4A Cluster in Alzheimer's Disease.The MS4A family: counting past 1, 2 and 3.Insulin-like growth factor I messenger RNA and protein are expressed in the human lymph node and distinctly confined to subtypes of macrophages, antigen-presenting cells, lymphocytes and endothelial cells.The use of ofatumumab in the treatment of B-cell malignancies.MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.Evaluation of Known Defective Signaling-Associated Molecules in Patients Who Primarily Diagnosed as Common Variable Immunodeficiency.Novel susceptibility loci for Alzheimer's disease.Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab.Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cellsMultivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity.The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
P2860
Q28277551-7E75A88C-8FC0-413A-933E-F87AA43D0764Q28742585-90DF37B1-A1A8-4FC8-9559-0977CFFD3AB9Q33534692-1B7487E3-281B-4EBE-A0E8-2F45497B1C0AQ34277857-B02F2A39-32D0-4D9C-8370-EC49A8301824Q34484879-E7166013-AA30-439C-B869-53B5297C368DQ35783537-895D4FFB-18CF-43E3-90FE-2A230FC3A5F0Q36190150-F2090F24-1469-4444-886A-9BB84DDD2B66Q36411784-7615C5F6-C242-4FF8-8640-B3B7D0884700Q37011495-903E8CD3-3072-47B9-8784-28A30CAEEF4BQ37017215-8A26DE6E-9185-47D5-BA4E-6A79118D484AQ37448352-6EC64736-745A-47E1-98DD-527334709532Q38224993-3D10D261-9F41-430F-841C-201CB1F2C4DDQ38401877-1800D0E7-C545-47F6-A06E-0D7C5826F895Q38418306-B1A0C200-8701-4EC0-8ECB-6862BE1F430EQ38603992-A1AB414F-6216-401E-B03D-9779A75EED87Q38711882-64F22AC0-FD7A-4EEE-88FB-71A2BCBB094EQ38716531-1617FB0F-D4D7-401D-AA50-365DDA6A96CAQ38733785-6ACD7F0C-CE42-4D7B-9B57-F6E639DE1115Q38767112-F1900CE5-0AAC-46DD-889C-38285F140E0FQ38801607-EFD1D386-109D-4D4E-9799-64DB5A59D59AQ38994546-ED964631-13C5-4BAE-A48A-4F559AC7A8B5Q39157250-C50722BC-FA9D-43CF-93EF-D15FC186669DQ39455947-58CF621D-477B-4302-B2AA-C9D3A2A59179Q40297342-8A7D1FC7-33CE-494B-9E6B-3243FF34950EQ41966195-AC996C86-248E-4D64-B7D4-A1180292E9ABQ42254939-6FD289C3-7A65-4CD1-B86B-FE2BB9050E94Q42372842-A5F6F036-9AAC-4D50-9132-6B87076C96E2Q47688545-40282994-31C7-4B6D-BC10-0C5918030B29Q49177202-1227C0B2-5047-491D-825D-BD9DF7E207E8Q52681376-41B7C298-8ED6-4756-8B7A-87C1D3E22AE4
P2860
CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@en
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@nl
type
label
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@en
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@nl
prefLabel
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@en
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@nl
P2093
P2860
P356
P1476
CD20 homo-oligomers physically ...... d calmodulin-binding proteins.
@en
P2093
Haidong Li
Julie P Deans
Maria J Polyak
Neda Shariat
P2860
P304
18545-18552
P356
10.1074/JBC.M800784200
P407
P577
2008-05-12T00:00:00Z